Drug firm Orchid Chemicals & Pharmaceuticals today said it has received final approval from the US health regulator for its generic Venlafaxine capsules, used in the treatment of depression.
The final approval from the United States Food and Drug Administration (USFDA) is for its abbreviated new drug application (ANDA) for Venlafaxine extended release capsules in strengths of 37.5 mg, 75 mg and 150 mg, Orchid Chemicals & Pharmaceuticals said in a filing to the Bombay Stock Exchange (BSE).
Venlafaxine extended release capsules are used for treating major depressive disorders (MDD) and falls under the central nervous system (CNS) category.
Venlafaxine was introduced by drug-maker Wyeth in 1993 under the brand name Effexor.
Shares of Orchid Chemicals & Pharmaceuticals were being quoted at Rs 254 apiece in afternoon trade on the BSE today, up 0.89% from their previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app